HR 3204 · 113th Congress 2013–2015, ended

Drug Quality and Security Act

Latest action · Nov 27, 2013 Became Public Law No: 113-54.

Progress

Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.

  1. IntroducedSep 27, 2013
  2. Passed HouseSep 28, 2013
  3. Passed SenateNov 18, 2013
  4. To the PresidentNov 21, 2013
  5. Became lawNov 27, 2013Public Law 113-54

Summary

(This measure has not been amended since it was introduced. The summary has been expanded because action occurred on the measure.)

Drug Quality and Security Act - Title I: Drug Compounding - Compounding Quality Act - (Sec. 102) Amends the Federal Food, Drug, and Cosmetic Act (FFDCA) with respect to the regulation of compounding drugs. Exempts compounded drugs from new drug requirements, labeling requirements, and track and trace requirements if the drug is compounded by or under the direct supervision of a licensed pharmacist in a registered outsourcing facility and meets applicable requirements.

Establishes annual registration requirement for any outsourcing facility. Requires a facility to report biannually to the Secretary of Health and Human Services (HHS) on what drugs are compounded in the facility and to submit adverse event reports. Subjects such facilities to a risk-based inspection schedule.

Requires the Secretary to: (1) publish a list of drugs presenting demonstrable difficulties for compounding that are reasonably likely to lead to an adverse effect on the safety or effectiveness of the drug, taking into account the risk and benefits to patients; and (2) convene an advisory committee on compounding before creating the list.

Requires the Secretary to assess an annual establishment fee on each outsourcing facility and a reinspection fee, as necessary.

(Sec. 103) Prohibits the resale of a compounded drug labeled “not for resale,” or the intentional falsification of a prescription for a compounded drug. Deems a compounded drug to be misbranded if its advertising or promotion is false or misleading in any particular.

(Sec. 105) Requires the Secretary to receive submissions from state boards of pharmacy: (1) describing any disciplinary actions taken against compounding pharmacies or any recall of a compounded drug, and (2) expressing concerns that a compounding pharmacy may be violating the FFDCA.

(Sec. 106) Revises compounding pharmacy requirements to repeal prohibitions on advertising and promotion of compounded drugs by compounding pharmacies and repeal the requirement that prescriptions filled by a compounding pharmacy be unsolicited.

(Sec. 107) Requires the Comptroller General (GAO) to report on pharmacy compounding and the adequacy of state and federal efforts to assure the safety of compounded drugs.

Title II: Drug Supply Chain Security - Drug Supply Chain Security Act - (Sec. 202) Establishes requirements to facilitate the tracing of prescription drug products through the pharmaceutical supply distribution chain.

Requires the Secretary to establish standards for the exchange of transaction documentation, which shall include transaction information, transaction history, and transaction statements.

Requires the Secretary to establish processes to: (1) provide waivers of requirements, including for undue economic hardship or emergency medical reasons; (2) provide exceptions to requirements relating to product identifiers if a product is packaged without sufficient space to bear the information; and (3) determine other products or transactions that should be exempt from the requirements of this Act.

Establishes requirements for drug manufacturers, wholesalers, dispensers, and repackagers to ensure that all prior transaction information is provided at each transfer of ownership.

Requires a manufacturer, wholesale distributor, dispenser, and repackager, in the event of a recall or for the purpose of investigating a suspect product or an illegitimate product, to provide within a reasonable time the applicable transaction documentation upon request by the Secretary or other appropriate federal or state official.

Requires a manufacturer or repackager to affix or imprint a product identifier on each package and homogenous case intended to be introduced in a transaction into commerce. Excepts from this requirement with respect to unique device identifiers any products required to have a standardized numerical identifier.

Requires a manufacturer, wholesale distributor, dispenser, or repackager to ensure that each of its trading partners is authorized.

Requires a manufacturer, wholesale distributor, dispenser, and repackager to implement systems to: (1) investigate suspect products; and (2) handle illegitimate products, including through quarantine, disposal, and appropriate notice to the Secretary and, as necessary, trading partners.

Requires manufacturers, wholesale distributors, and repackagers to verify returned products before further distribution.

(Sec. 203) Prescribes additional requirements related to the tracing of products at the package level (enhanced drug distribution security) which shall go into effect ten years after enactment of this Act.

Authorizes a dispenser to enter into a written agreement with a third party, including an authorized wholesale distributor, that requires the third party to maintain confidentially any information and statements required to be maintained. Requires the Secretary to provide for alternative methods of compliance with such additional drug distribution security requirements.

Directs the Secretary to contract with a private, independent consulting firm with expertise to conduct a technology and software assessment that looks at the feasibility of dispensers with 25 or fewer full-time employees conducting interoperable, electronic tracing of products at the package level.

Requires the Secretary to: (1) establish one or more pilot projects and hold public meetings to enhance the safety and security of the pharmaceutical distribution supply chain, (2) issue a final guidance document that outlines and makes recommendations with respect to the system attributes necessary to enable secure tracing at the package level, and (3) identify and make recommendations with respect to the standards necessary for adoption in order to support the secure interoperable electronic data exchange among the pharmaceutical distribution supply chain that comply with a form and format developed by a widely recognized international standards development organization.

(Sec. 204) Requires the Secretary to establish standards for the licensing of wholesale distributors and third party logistics providers.

(Sec. 205) Preempts state and local requirements related to tracing drugs through the distribution system, and licensure of wholesale distributors and third party logistics providers.

(Sec. 206) Subjects violations of this Act to specified criminal and civil penalties.

Deems misbranded any drug failing to bear its required product identifier.

Recorded votes 1

Newest first. Open one to see how every member voted.

Roll callQuestionResultDate
Senate 234Cloture Motion Agreed to97–1Nov 12, 2013

Cosponsors 10

Members who signed on, in the order they did. All signed on Sep 27, 2013.

SeatCosponsorSigned on
D-CODiana DeGetteOriginalSep 27, 2013
D-NJFrank Pallone, Jr.OriginalSep 27, 2013
D-TXGene GreenOriginalSep 27, 2013
R-VAH. Morgan GriffithOriginalSep 27, 2013
D-CAHenry A. WaxmanOriginalSep 27, 2013
D-UTJim MathesonOriginalSep 27, 2013
D-MIJohn D. DingellOriginalSep 27, 2013
R-PAJoseph R. PittsOriginalSep 27, 2013
R-OHRobert E. LattaOriginalSep 27, 2013
R-PATim MurphyOriginalSep 27, 2013

Committees 1

Where it was sent and what each committee and subcommittee did with it, in order.

ChamberCommitteeWhat it did
HouseEnergy and Commerce Committee
Referred Sep 27, 2013

Actions 28

Everything that happened, newest first.

  1. Nov 27, 2013Signed by President.
  2. Nov 27, 2013Became Public Law No: 113-54.
  3. Nov 21, 2013Presented to President.
  4. Nov 18, 2013Considered by Senate. (consideration: CR S8071-8076)
  5. Nov 18, 2013Cloture motion withdrawn by unanimous consent in Senate. (consideration: CR S8071)
  6. Nov 18, 2013Motion by Senator Reid to commit to Senate Committee on Health, Education, Labor, and Pensions with instructions to report back forthwith with amendment SA 2035 withdrawn in Senate. (consideration: CR S8071)
  7. Nov 18, 2013Passed/agreed to in Senate: Passed Senate without amendment by Voice Vote.
  8. Nov 18, 2013Message on Senate action sent to the House.
  9. Nov 14, 2013Motion to proceed to consideration of measure agreed to in Senate by Voice Vote.
  10. Nov 14, 2013Measure laid before Senate by motion. (consideration: CR S8026, S8027)
  11. Nov 14, 2013Motion by Senator Reid to commit to Senate Committee on Health, Education, Labor, and Pensions with instructions to report back forthwith with amendment SA 2035 made in Senate. (consideration: CR S8026; text: CR S8026)
  12. Nov 14, 2013Cloture motion on the measure presented in Senate. (consideration: CR S8027; text: CR S8027)
  13. Nov 13, 2013Motion to proceed to measure considered in Senate. (consideration: CR S7973-7996)
  14. Nov 12, 2013Motion to proceed to consideration of measure made in Senate. (consideration: CR S7949-7950)
  15. Nov 12, 2013Cloture on the motion to proceed to the measure invoked in Senate by Yea-Nay Vote. 97 - 1. Record Vote Number: 234. (consideration: CR S7949-7950; text: CR S7949)
  16. Nov 7, 2013Motion to proceed to consideration of measure made in Senate. (consideration: CR S7891-7894, S7909-7920, S7923-7924)
  17. Nov 7, 2013Cloture motion on the motion to proceed to the measure presented in Senate. (consideration: CR S7923-7924; text: CR S7923-7924)
  18. Nov 6, 2013Motion to proceed to consideration of measure made in Senate. (consideration: CR S7841-7845, S7846-7864)
  19. Nov 6, 2013Motion to proceed to consideration of measure withdrawn in Senate. (consideration: CR S7864)
  20. Nov 5, 2013Read the second time. Placed on Senate Legislative Calendar under General Orders. Calendar No. 236.
  21. Nov 4, 2013Read the first time. Placed on Senate Legislative Calendar under Read the First Time.
  22. Sep 30, 2013Received in the Senate.
  23. Sep 28, 2013Mr. Upton moved to suspend the rules and pass the bill.
  24. Sep 28, 2013Considered under suspension of the rules. (consideration: CR H5946-4965)
  25. Sep 28, 2013DEBATE - The House proceeded with forty minutes of debate on H.R. 3204.
  26. Sep 28, 2013Passed/agreed to in House: On motion to suspend the rules and pass the bill Agreed to by voice vote. (text: CR H5946-5960)
  27. Sep 27, 2013Introduced in House
  28. Sep 27, 2013Referred to the House Committee on Energy and Commerce.

In the Congressional Record 10

Days the Record’s own index lists this bill, newest first, with the pages and the members it names. Pages starting H are the House, S the Senate, E Extensions of Remarks.

WhereIn the RecordMembersDate
SenateDebate and remarks S8071–S8076, S8079, S8080Carl Levin D-MI, Dianne Feinstein D-CA, Elizabeth Warren D-MA, Harry Reid D-NV, John Boozman R-AR, John McCain R-AZ, Johnny Isakson R-GA, Lamar Alexander R-TN, Mark R. Warner D-VA, Richard Burr R-NC, Tom Coburn R-OK, Tom Harkin D-IANov 18, 2013
SenateDebate and remarks S8013, S8024, S8026–S8030Amendments S8026, S8057Motions S8026Cloture motions S8027Lists S8025, S8028Organizations supporting H.R. 3204, Drug Quality and Security ActStaff and Senators who worked on H.R. 3204, Drug Quality and Security ActAmy Klobuchar D-MN (cloture motion), Angus S. King Jr. I-ME (cloture motion), Barbara A. Mikulski D-MD, Benjamin L. Cardin D-MD (cloture motion), Bill Nelson D-FL (cloture motion), Christopher A. Coons D-DE (cloture motion), David Vitter R-LA, Debbie Stabenow D-MI (cloture motion), Harry Reid D-NV (amendment, cloture motion, motion), Jack Reed D-RI (cloture motion), Joe Manchin III D-WV (cloture motion), Mark Begich D-AK (cloture motion), Mark R. Warner D-VA (cloture motion), Michael F. Bennet D-CO, Pat Roberts R-KS, Patrick J. Leahy D-VT (cloture motion), Richard Blumenthal D-CT (cloture motion), Sheldon Whitehouse D-RI (cloture motion), Tim Kaine D-VA (cloture motion), Tom Coburn R-OK, Tom Harkin D-IA (cloture motion), Tom Udall D-NM (cloture motion)Nov 14, 2013
SenateDebate and remarks S7965, S7967–S7970, S7974, S7981, S7984, S7985, S7986Amendments S8008Motions S7973Al Franken D-MN, David Vitter R-LA (amendment), Edward J. Markey D-MA, Harry Reid D-NV, Richard Burr R-NC, Tom Harkin D-IANov 13, 2013
SenateDebate and remarks S7938, S7940–S7944Motions S7937Cloture motions S7949Recorded votes S7949cloture motion on motion to proceedAl Franken D-MN (cloture motion), Barbara A. Mikulski D-MD (cloture motion), Barbara Boxer D-CA (cloture motion), Benjamin L. Cardin D-MD (cloture motion), Brian Schatz D-HI (cloture motion), Christopher A. Coons D-DE (cloture motion), Debbie Stabenow D-MI (cloture motion), Harry Reid D-NV (cloture motion, motion), Jeff Merkley D-OR (cloture motion), Kirsten E. Gillibrand D-NY (cloture motion), Lamar Alexander R-TN, Mark Begich D-AK (cloture motion), Patrick J. Leahy D-VT (cloture motion), Patty Murray D-WA (cloture motion), Richard J. Durbin D-IL (cloture motion), Sheldon Whitehouse D-RI (cloture motion), Tom Harkin D-IA (cloture motion), Tom Udall D-NM (cloture motion)Nov 12, 2013
SenateDebate and remarks S7923Motions S7891Cloture motions S7923Al Franken D-MN (cloture motion), Barbara A. Mikulski D-MD (cloture motion), Barbara Boxer D-CA (cloture motion), Benjamin L. Cardin D-MD (cloture motion), Brian Schatz D-HI (cloture motion), Christopher A. Coons D-DE (cloture motion), Debbie Stabenow D-MI (cloture motion), Harry Reid D-NV (cloture motion, motion), Jeff Merkley D-OR (cloture motion), Kirsten E. Gillibrand D-NY (cloture motion), Mark Begich D-AK (cloture motion), Patrick J. Leahy D-VT (cloture motion), Patty Murray D-WA (cloture motion), Richard J. Durbin D-IL (cloture motion), Sheldon Whitehouse D-RI (cloture motion), Tom Harkin D-IA (cloture motion), Tom Udall D-NM (cloture motion)Nov 7, 2013

Research

What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.

Congressional Budget Office cost estimate

  1. Sep 27, 2013H.R. 3204, the Drug Quality and Security ActAs posted on the website of the House of Representatives on September 26, 2013 (UPTON_006)

Constitutional authority

Congress has the power to enact this legislation pursuant to the following: This bill is enacted pursuant to the power granted to Congress under Article I, Section 8, Clause 3 of the United States Constitution. (Commerce Clause)

The sponsor’s statement, as printed in the page H5922.

CRS reports 13

Congressional Research Service work that CRS links to this bill or the law it became, newest first.

About this bill 1

Products that name it in their title: its number, its law number or one of its short titles.

ProductTitleKindPublished
R43290The Proposed Drug Quality and Security Act (H.R. 3204) ArchivedReportOct 31, 2013

Also cite it 12

Products on other subjects that cite it, usually among other measures.

Amendments 8

Amendments offered to this bill.

AmendmentDescriptionOffered byStatus
SA 2007No description on fileKirsten E. Gillibrand D-NYSenate amendment submitted
SA 2008No description on fileKirsten E. Gillibrand D-NYSenate amendment submitted
SA 2024No description on fileDavid Vitter R-LASenate amendment submitted
SA 2033To change the enactment date.Harry Reid D-NVProposed amendment SA 2033 withdrawn in Senate. (consideration: CR S8071)
SA 2034Of a perfecting nature.Harry Reid D-NVSA 2034 fell when SA 2033 withdrawn. (consideration: CR S8071)

Related bills 3

Companion bills and other measures the record links to this one.

BillTitleRelationshipLatest action
S 957Drug Supply Chain Security ActRelated billMay 15, 2013
S 959Pharmaceutical Quality, Security, and Accountability ActRelated billJun 19, 2013
HR 1919Safeguarding America's Pharmaceuticals Act of 2013Related billJun 4, 2013

Titles 11

Every title it has carried, official and short, at each stage.

Official Title as Introduced
To amend the Federal Food, Drug, and Cosmetic Act with respect to human drug compounding and drug supply chain security, and for other purposes.
Short Titles as Introduced
Drug Quality and Security Act
Short Titles as Passed House
Drug Quality and Security Act
Short Titles as Passed Senate
Drug Quality and Security Act
Short Titles as Enacted
Drug Quality and Security Act
Short Titles as Passed House for portions of this bill
Drug Supply Chain Security Act
Compounding Quality Act
Short Titles as Passed Senate for portions of this bill
Drug Supply Chain Security Act
Compounding Quality Act
Short Titles as Enacted for portions of this bill
Drug Supply Chain Security Act
Compounding Quality Act

Subjects

Assigned by the Library of Congress. Policy area: Health.

Text 4

Each version as it was printed, newest first.

  1. —Enrolled Bill
  2. Nov 5, 2013Placed on Calendar Senate
  3. Sep 28, 2013Engrossed in House
  4. Sep 27, 2013Introduced in House

Support LegiList

This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.

Processed by Stripe in a separate window. LegiList never sees card details. Other amounts

Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.